InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.006 -0.037 (-86.05%)+
Announcement
Release
29 Jul 2026 2:10PM
Price at Release
$0.043
Full Release
download
Summary
Chimeric Therapeutics Limited, an Australian cell therapy company, has announced the receipt of $1.62 million as an advance on its FY26 R&D tax incentive. This funding, provided by Endpoints Capital, is secured against the company's anticipated FY26 research and development tax incentive from the Australian Government, which provides a refundable tax offset of up to 43.5% for eligible activities. The funds will be used to support ongoing Phase 1/2 clinical trials and general working capital, as the company is conducting a strategic review. The agreement includes a repayment plan aligned with the anticipated tax incentive receipt by December 31, 2026, with early repayment options. Additionally, the company has discharged its previous R&D facility with Radium Capital.
Key Points
  • Chimeric Therapeutics receives $1.62M advance on FY26 R&D tax incentive.
  • Funded by Endpoints Capital, secured against anticipated FY26 R&D tax incentive.
  • Funds support Phase 1/2 clinical trials and general working capital.
  • Facility repayment aligned with FY26 R&D tax incentive receipt by December 31, 2026.
  • Previous R&D facility with Radium Capital repaid and discharged.
  • Australian Government provides up to 43.5% refundable tax offset for eligible R&D activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.